Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAS-101 in Stable Sickle Cell Disease
NCT07566494Phase 1Recruiting
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Jul 2026
- Primary completion
- Apr 2027
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VAS101 in sickle cell disease (SCD), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Safety and Tolerability of VAS-101. Started Jul 2026; status: recruiting.
02
Drugs
VAS101
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT07566494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07566494.